false
0001692415
0001692415
2026-11-18
2026-11-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 18, 2026
CO-DIAGNOSTICS,
INC.
(Exact
name of registrant as specified in its charter)
| Utah |
001-38148 |
46-2609363 |
(State or other jurisdiction
of incorporation) |
(Commission
File
Number) |
(I.R.S.
Employer
Identification
No.) |
2401
S. Foothill Drive, Suite D, Salt Lake City, Utah 84109
(Address
of principal executive offices) (Zip Code)
(801)
438-1036
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.001 par value per share |
|
CODX |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
Funding
of Additional Loan
On
November 18, 2026, Co-Diagnostics, Inc. (the “Company”) borrowed the additional loan contemplated by the Loan Agreement,
dated as of October 9, 2026 (the “Loan Agreement”), between the Company and J.J. Astor & Co. (the “Lender”)
as disclosed in the Company’s Current Report on Form 8-K filed on October 13, 2026. The Lender funded $1.0 million (the “Additional
Loan”), and the Company issued to the Lender a senior secured convertible installment promissory note having an original principal
amount of $1.35 million (the “Additional Note”). The original principal amount of the Additional Note reflects a factor rate
of 1.35 times the funded amount. The Lender retained a $40,000 origination fee, resulting in net cash proceeds to the Company of $960,000
before other transaction expenses. The Company intends to use the net proceeds for general working capital purposes.
The
Additional Note has an original issue date of November 18, 2026, requires 30 weekly installment payments of $45,000 beginning November
25, 2026, and has a final maturity date of June 16, 2027. The Additional Note is secured by a senior-priority lien on substantially all
assets of the Company and its existing subsidiaries as subsidiary guarantors pursuant to that certain Pledge and Security Agreement,
dated October 9, 2026 and the Subsidiary Guarantee dated October 9, 2026.
The
Company may prepay the Additional Note at any time without penalty. If the Additional Note is paid in full within 45 days after its funding
date and no event of default has occurred, the repayment amount will be reduced to reflect a factor rate of 1.29 times the applicable
funded amount, less all weekly installment payments previously made. Upon an event of default, the outstanding balance becomes immediately
due and payable, the outstanding principal amount of all notes issued under the Loan Agreement is increased to 120% of the then-outstanding
principal amounts, bear default interest at 19% per annum, compounded daily (the “Default Amount”) and may be converted by
the Lender at the event of default Conversion Price (as defined in the Loan Agreement).
The
Lender may convert all or any portion of the payment amount under the Additional Note into shares of the Company’s common stock
(the “Conversion Shares”) at a conversion price equal to the greater of (i) 90% of the lowest volume-weighted average price
of the common stock during the 10 consecutive trading days immediately preceding the conversion date and (ii) the minimum price determined
under applicable Nasdaq listing rules, subject to a floor price equal to 20% of the Nasdaq minimum price and other customary adjustments.
On the six-month anniversary of the execution of the Loan Agreement, and every six months thereafter, the floor price will be reset to
the lower of (i) the floor price then in effect or (ii) 20% of the lowest volume weighted average price of the Company’s common
stock during the twenty trading days preceding such reset; provided that the floor price will not be reduced below 20% of the Nasdaq
minimum price unless and until the Company obtains stockholder approval.
In
connection with the funding, the Company and the Lender agreed to waive certain conditions under the Loan Agreement that otherwise would
have required the Additional Loan to be requested and funded no earlier than December 8, 2026 and on at least five business days’
notice. The parties also waived the conditions that the closing price of the Company’s common stock on the trading day immediately
preceding the funding date be at least $1.00 per share and that the Company’s previously approved reverse stock split has become
effective before the funding date. The Company is required to cause the reverse stock split to become effective on or before November
24, 2026, and failure to do so constitutes an event of default under the Additional Note. The waiver does not waive any other condition
to funding the Additional Loan.
The
foregoing description of the Additional Note does not purport to be complete and is qualified in its entirety by reference to the full
text of the Additional Note, which is filed as Exhibit 4.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item
2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
Item
3.02 Unregistered Sales of Equity Securities.
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.
The
Company issued the Additional Note in reliance on the exemption from the registration requirements of the Securities Act of 1933, as
amended (the “Securities Act”), provided by Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D promulgated thereunder.
The Lender represented that it is an “accredited investor” as defined in Rule 501(a) of Regulation D. Neither the Additional
Note nor any shares of common stock issuable upon conversion of the Additional Note have been registered under the Securities Act. Any
such shares issued absent registration may not be offered or sold in the United States absent registration or an applicable exemption
from registration.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description |
| 4.1 |
|
Senior Secured Convertible Note issued to J.J. Astor & Co., dated November 18, 2026. |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
CO-DIAGNOSTICS, INC. |
| Dated:
November 20, 2026 |
|
|
| |
By: |
/s/
Dwight H. Egan |
| |
Name: |
Dwight H. Egan |
| |
Title: |
Chief Executive Officer |